[ad_1]
SHIJIAZHUANG, China, April 30, 2022 /PRNewswire/ — Yiling Pharmaceutical released its 2021 Annual Report Friday and disclosed the main development statistics. According to the report, its annual revenue reached USD 1.53 billionan increase of 15.19% from last year, besides, net profit attributable to equity holders reached USD 203.75 millionachieving a 10.27% growth YoY.
The annual revenue of Tongxinluo Capsules, Shensong Yangxin Capsules, and Qili Qiangxin Capsules, Yiling’s 3 main products for cardio-cerebrovascular diseases, reached USD 687.4 millionaccounting for 44.82% of the overall revenue, achieving a 31.56% YoY growth despite the Covid-19 hit. Notably, in …
Full story available on Benzinga.com
[ad_2]
Source link
